Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glofit-GemOx Bridging to Liso-cel in Relapsed/Refractory Aggressive B-cell Lymphomas
NCT07711483Phase 2Recruiting
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in diffuse large B-cell lymphoma (DLBCL), sponsored by Massachusetts General Hospital. Primary endpoint: Complete Response Rate to lisocabtagene maraleucel up to 2 years. Started Sep 2026; status: recruiting.
02
Drugs
glofitamab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT07711483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07711483.